
The Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's warehouse at Wadki in Pune, citing misbranding of Reactin Plus Tablets and storage deficiencies. The order was passed on 1 October after fresh proceedings completed following Bombay High Court directions. The FDA had withdrawn its earlier August action and issued a revised show-cause notice on 4 September, received a written reply on 11 September, and held a personal hearing on 21 September.

The FDA found that Reactin Plus, a Schedule H prescription drug, carried unauthorised claims describing it as an analgesic and depicting relief from muscular pain, constituting misbranding under the Drugs and Cosmetics Act, 1940. Inspections also revealed medicines stored on the floor, dust accumulation, expired stock not segregated, and discrepancies between computerised records and physical inventory. Cipla called the decision 'disappointing', said the facility complies with protocols, and is reviewing the order and evaluating further options.
Coverage is uniform straight reporting across all sources. Every outlet reproduces the FDA's findings on Reactin Plus misbranding, storage lapses and the procedural sequence ordered by the Bombay High Court, and each carries Cipla's statement calling the decision 'disappointing' and pledging a review. Hindustan Times, Indian Express, Livemint and CNBC-TV18 all give Commissioner Tukaram Mundhe's remark that the aim is compliance, not enforcement, identical wording. No outlet editorialises. The one factual variation is India Today's figure of seized Reactin Plus stock worth Rs 11.2 lakh from the earlier August action, which no other source repeats. The next step is Cipla's stated evaluation of further options against the order.
Coverage: 16 sources, 16 neutral
Sources (16): economictimes.indiatimes.com (neutral report), indianexpress.com (neutral report), rediff.com (neutral report), thefederal.com (neutral report), ndtvprofit.com (neutral report), livemint.com (neutral report), cnbctv18.com (neutral report), indiatoday.in (neutral report), timesofindia.indiatimes.com (neutral report), economictimes.indiatimes.com (2) (neutral report), economictimes.indiatimes.com (3) (neutral report), odishabytes.com (neutral report), business-standard.com (neutral report), medicaldialogues.in (neutral report), hindustantimes.com (neutral report), indianexpress.com (2) (neutral report)
This brief was synthesised by AI from the 16 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 5 October 2026: this story now draws on 16 sources.